---
title: Improve gait using Percept neurostimulation
nct_id: NCT05820074
status: RECRUITING
sponsor: Swiss Federal Institute of Technology
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05820074"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05820074"
last_fetched: "2026-05-10T14:05:17.216Z"
source: "Parkinson's Pathways (curated)"
---
# Improve gait using Percept neurostimulation

**Goal (in five words):** Improve gait using Percept neurostimulation

**Official Title:** Investigating Neural Biomarkers for Gait in Parkinson's Patients

**Trial ID:** [NCT05820074](https://clinicaltrials.gov/study/NCT05820074)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Swiss Federal Institute of Technology
- **Target Enrollment:** 60 participants
- **Start Date:** 2023-04-13
- **Completion Date:** 2025-03
- **Conditions:** Parkinson Disease, Gait Disorders, Neurologic
- **Interventions:** Neural Activity Recording, Movement Parameter Recording, Neuromodulation
- **Intervention Types:** DIAGNOSTIC_TEST, OTHER

## Summary For Families

They're looking for specific brain signal patterns tied to walking and balance problems in Parkinson's, so future brain stimulation can be timed or targeted better to reduce freezing, falls, and shuffling. The team records brain rhythms from the implanted Percept PC neurostimulator while tracking movement during walking, comparing data with stimulation turned off to identify electrical signatures that could guide how deep brain stimulation is adjusted alongside medications like levodopa. Adults 18 and up with non-tremor dominant idiopathic PD who have postural instability and gait disturbance, who already have a Percept PC and can tolerate being off stimulation, plus healthy controls without neurological or sensory issues, are being enrolled; people with MoCA under 20 or other interfering conditions are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

All participants

* must have given informed consent as documented by signature
* agree to comply with the study procedures

Healthy control group

* no neurological, orthopedic, or rheumatologic disease history
* no identified sensory impairment.
* no epilepsy and self-diagnosed acute or chronic psychiatric disorders

Parkinson's Patients

* non-tremor dominant idiopathic PD patients
* presence of postural instability (UPDRS \>1 for postural instability \[17\]), gait disturbance, and absence of other causes of reduced balance
* Implanted with Percept™ PC neurostimulator
* Able to be in the stimulation OFF

Exclusion Criteria:

* Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \< 20
* History of physical or neurological condition that interferes with study procedures
* Social and/or personal circumstances interfering with the ability to come to the session
```

## Locations (1)

- Cereneo, Vitznau, Canton of Lucerne, Switzerland _(47.0101, 8.4842)_
  - Andreas Luft, Professor — (CONTACT) — +41 44 255 55 11 — andreas.luft@usz.ch
  - Lena Salzmann, PhD student — (CONTACT) — +41 44 510 72 34 — lena.salzmann@hest.ethz.ch

## Central Contacts

- Lena Salzmann, MSc — (CONTACT) — +41788248679 — lena.salzmann@hest.ethz.ch
- Olivier Lambercy, PhD — (CONTACT) — oliver.lambercy@hest.ethz.ch

---

*Canonical: https://parkinsonspathways.com/trial/NCT05820074*  
*HTML version: https://parkinsonspathways.com/trial/NCT05820074*  
*Source data: https://clinicaltrials.gov/study/NCT05820074*